Multisystemic, Possibly Familial Sarcoidosis Ameliorated by an mTOR Inhibitor

Area of Science:

• Immunology
• Pharmacology
• Rheumatology

Background:

• Sarcoidosis is a multisystem inflammatory disease of unknown cause.
• It involves granuloma formation, potentially leading to organ damage and failure.
• Current treatments focus on inflammation reduction and symptom management without proven survival benefits.

Observation:

• A mother and son with chronic, aggressive, multiorgan sarcoidosis were treated with sirolimus.
• Sirolimus is a mammalian target of rapamycin (mTOR) inhibitor.
• Both patients demonstrated significant reduction in organ inflammation and symptom relief.

Findings:

• Sirolimus treatment led to marked reversal of inflammation in affected organs.
• Patients experienced profound relief from sarcoidosis symptoms.
• The treatment was effective in cases resistant to conventional therapies.

Implications:

• Mammalian target of rapamycin (mTOR) inhibition presents a potential therapeutic strategy for sarcoidosis.
• Sirolimus may offer a safe and effective option for drug-resistant systemic sarcoidosis.
• Further research into mTOR inhibitors for sarcoidosis is warranted.